Dinutuximab Beta Maintenance Therapy in Patients with High-Risk Neuroblastoma in First-Line and Refractory/Relapsed Settings—Real-World Data

Dinutuximab Beta Maintenance Therapy in Patients with High-Risk Neuroblastoma in First-Line and Refractory/Relapsed Settings—Real-World Data

Dinutuximab beta is approved for the maintenance treatment of patients with high-risk neuroblastoma (HR-NB), including patients with relapsed/refractory (R/R) disease. However, the data on its use in real-world clinical practice is limited. We retrospectively reviewed the clinical records of 54 pati...

Full description

Bibliographic Details
Main Authors: Aleksandra Wieczorek, Urszula Żebrowska, Marek Ussowicz, Agnieszka Sokół, Marzena Stypińska, Bożenna Dembowska-Bagińska, Katarzyna Pawińska-Wąsikowska, Walentyna Balwierz
Format: Article
Language:English
Published: MDPI AG 2023-08-01
Series:Journal of Clinical Medicine
Subjects:
dinutuximab beta
maintenance therapy
high-risk neuroblastoma
relapsed
refractory
real-world data
Online Access:https://www.mdpi.com/2077-0383/12/16/5252

Internet

https://www.mdpi.com/2077-0383/12/16/5252

Similar Items